Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11036436 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4107336 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL9053026 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4106728 | 0.95 | — | — | |
| SCHEMBL5860527 | 0.81 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL7919973 | 0.79 | MEN1 (0.61) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL7898330 | 0.76 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL26397994 | 0.76 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL11954753 | 0.76 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL695304 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516083-B2 | Nucleophilic catalysts for oxime linkage | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-06 | — | — | US | disclosed |
| US-20240335549-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | BAXALTA INCORPORATED (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024132865-A1 | ANTIMICROBIAL COMPOUND, PROCESS FOR PREPARING SAME AND USE OF THE ANTIMICROBIAL COMPOUND FOR PREPARING A COSMETIC OR PHARMACEUTICAL COMPOSITION | AEROCHEMICA DR. DEPPE GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389219-A1 | ANTIMICROBIAL COMPOUND, METHOD FOR ITS PREPARATION AND USE OF THE ANTIMICROBIAL COMPOUND FOR THE PREPARATION OF A COSMETIC OR PHARMACEUTICAL COMPOSITION | Aerochemica Dr. Deppe GmbH (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-11564992-B2 | Nucleophilic catalysts for oxime linkage | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-31 | — | — | US | disclosed |
| EP-4023247-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | Takeda Pharmaceutical Company Limited (JP) | 2022-07-06 | — | — | EP | disclosed |
| EP-4019049-A1 | METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20220175939-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | BAXALTA INCORPORATED (US) | 2022-06-09 | — | — | US | disclosed |
| EP-2849795-B1 | METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES | TAKEDA PHARMACEUTICALS CO (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3505186-B1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-2459224-A2 | BLOOD COAGULATION PROTEIN CONJUGATES | Baxter International Inc (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2459226-A2 | GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS | Lipoxen Technologies Limited (GB) | 2012-06-06 | — | — | EP | disclosed |
| US-20120035344-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | BAXTER HEALTHCARE S.A. (CH) | 2012-02-09 | — | — | US | disclosed |
| WO-2012016131-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011012850-A9 | GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011017055-A2 | BLOOD COAGULATION PROTEIN CONJUGATES | BAXTER INTERNATIONAL INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011012850-A2 | GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| US-20110027350-A1 | GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028693-A1 | BLOOD COAGULATION PROTEIN CONJUGATES | BAXTER INTERNATIONAL INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-1996006603-A1 | POLYALKYLENE OXIDE CONTAINING QUATERNARY AMMONIUM ANTIMICROBIAL AGENTS | ALCON LABORATORIES, INC. (US) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035344-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885TSHR 3015/4885 |
| US-11564992-B2 | Nucleophilic catalysts for oxime linkage | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885TSHR 3015/4885 |
| US-20220175939-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | SERPINA6, FCGRT, ALB | MEN1 2516/4885KMT2A 4056/4885TSHR 2956/4885 |
| US-20110028693-A1 | BLOOD COAGULATION PROTEIN CONJUGATES | F13B, F12, F2 | MEN1 3815/4885KMT2A 1975/4885TSHR 3460/4885 |
| US-20110027350-A1 | GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS | HPSE, GYPA, GBA2 | MEN1 3778/4885KMT2A 1292/4885TSHR 2965/4885 |
| US-20240335549-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | SERPINA6, FCGRT, ALB | MEN1 2516/4885KMT2A 4056/4885TSHR 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.